About theravance biopharma inc - TBPH
Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.
TBPH At a Glance
Theravance Biopharma, Inc.
901 Gateway Boulevard
South San, California 94080
| Phone | 1-650-808-6000 | Revenue | 107.46M | |
| Industry | Pharmaceuticals: Major | Net Income | 105.90M | |
| Sector | Health Technology | 2025 Sales Growth | 66.919% | |
| Fiscal Year-end | 12 / 2026 | Employees | 90 | |
| View SEC Filings |
TBPH Valuation
| P/E Current | 7.894 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 9.101 |
| Price to Sales Ratio | 8.968 |
| Price to Book Ratio | 3.22 |
| Price to Cash Flow Ratio | 4.04 |
| Enterprise Value to EBITDA | -93.628 |
| Enterprise Value to Sales | 6.736 |
| Total Debt to Enterprise Value | 0.104 |
TBPH Efficiency
| Revenue/Employee | 1,194,044.444 |
| Income Per Employee | 1,176,611.111 |
| Receivables Turnover | 1.125 |
| Total Asset Turnover | 0.256 |
TBPH Liquidity
| Current Ratio | 10.925 |
| Quick Ratio | 10.925 |
| Cash Ratio | 8.233 |
TBPH Profitability
| Gross Margin | 94.868 |
| Operating Margin | -12.326 |
| Pretax Margin | 120.27 |
| Net Margin | 98.54 |
| Return on Assets | 25.221 |
| Return on Equity | 44.845 |
| Return on Total Capital | 28.449 |
| Return on Invested Capital | 36.774 |
TBPH Capital Structure
| Total Debt to Total Equity | 25.444 |
| Total Debt to Total Capital | 20.283 |
| Total Debt to Total Assets | 15.548 |
| Long-Term Debt to Equity | 21.755 |
| Long-Term Debt to Total Capital | 17.343 |